coronary artery calcification in CKD patients and to the observation that CKD exists as an independent risk factor for incidence of stroke. 4, 5 Multiple hormonal, inflammatory, and nutritional factors may be implicated in the pathogenesis of the complex disease-state seen in ESRD. 6 These alterations include activation of proinflammatory cytokines, altered hepatic acute phase reactants, over activation of the reninangiotensin-aldosterone system, and adipocytokine dysfunction. 6 Adipocytokines like leptin and resistin have been previously shown to have independent association with risk and severity of chronic kidney disease. 7 Secreted in quantities proportional to fat mass, leptin has impaired clearance in CKD and is considered a uremic toxin that "plays a key role in the pathogenesis of complications associated with CKD such as cachexia, protein energy wasting, chronic inflammation, insulin resistance, cardiovascular damages, and bone complications." 8, 9 Leptin plays a significant role in regulating diet and energy expenditure. Furthermore, when chronically elevated, it also plays a role in the etiology of hypertension. 10 Although the mechanism of inducing elevated blood pressure has not been well-defined, one can infer that chronic hyperleptinemia may contribute to the various deleterious end-organ effects observed in hypertensive patients, such as left-ventricular hypertrophy, nephropathy, and retinopathy. 10 Prior studies have demonstrated that ESRD patients have elevated plasma resistin levels compared with normal-elevated resistin has recently been shown to be correlated with all-cause mortality in a systematic review and meta-analysis. 11 Inflammatory processes in humans such as obesity and insulin resistance have been shown to be correlated with elevated levels of adipocyte-derived resistin. 12 In the pediatric population, resistin is also known to play a role in the inflammatory milieu, displaying increased serum levels with decreased glomerular filtration rate.
13,14
In addition, ESRD has displayed correlation with metabolic syndrome (MetS), a condition identified by a cluster of cardiovascular risk factors (elevated blood pressure, dyslipidemia, elevated fasting glucose, central obesity), which even further indicates the presence of a complex systemic microenvironment in these patients. 15, 16 It is clear that care for ESRD patients proposes a considerable global economic burden with estimates reaching greater than $1 trillion annually. 17 Small advancements in early identification of ESRD and its comorbid conditions may make a large impact on the natural disease progression and its economic burden. Despite emerging understanding of biomarker contribution to the progression of CKD, there is a current paucity data to support sensitive and specific biomarkers as predictors of CKD progression. Microarray technology presents a novel method to rapidly profile patients for plasma biomarker concentrations. These levels offer a snapshot into the systemic circulating factors that may contribute to the pathogenesis of vascular comorbid conditions like stroke, coronary artery disease (CAD), acute coronary syndrome (ACS), and congestive heart failure (CHF). Insight into these aggregated aberrancies may provide a framework for future advances in risk stratification and predictive modelling.
Our study provides a cross-sectional observation of this microenvironment in 83 ESRD patients by comparing plasma metabolic and inflammatory biomarker concentrations between groups with and without a history of the aforementioned vascular comorbidities.
Methods
Our study represents a cross-sectional observational study of sequential ESRD patients currently on hemodialysis (HD) and a 10-year retrospective review of their history of comorbid vascular conditions.
Biomarker Evaluation
Under the approval of the institutional review board, plasma samples were collected from 83 patients with ESRD prior to hemodialysis from November 1 to 2, 2013. The patients displayed a representative population to the national demographics of ESRD patients (►Table 1).
18 Samples were stored at -80°C. Inflammatory and metabolic biochips were purchased from RANDOX (Co. Antrim, Northern Ireland) to profile concentrations of C peptide, ferritin, insulin, leptin, resistin, tumor necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1), interleukin-1α (IL-1α), IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, vascular endothelial growth factor (VEGF), endothelial growth factor (EGF), interferon-γ (IFN-γ), and monocyte chemoattractant protein-1 (MCP-1).
Retrospective Medical Record Review
The electronic medical records for 83 patients were accessed and searched for evidence of current or prior diagnoses in the following conditions: cerebrovascular accident, transient ischemic attack, or stroke (encompassed under our label as "stroke"); unstable angina, ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction (encompassed under our label as "ACS"); heart failure, systolic heart failure, diastolic heart failure, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction (encompassed under our label as "CHF"; coronary artery disease (CAD). Patients were selected sequentially. Patient's history of the aforementioned comorbidities was assigned in a binary fashion by detailed review of ICD-9 diagnosis codes, and physician notes (history and physicals, discharge summaries, nephrology progress notes, cardiology progress Note: Baseline demographic data on 83 hemodialysis patients notes, and neurology progress notes) over a retrospective period of 10 years from the time of sample collection.
Statistical Analysis
All data will be analyzed using GraphPad Prism Software (San Diego, CA). Unpaired, nonparametric t-tests were conducted to determine the significance of patterns among variables. Statistical significance was defined by p 0.05.
Results
Of 
Conclusion
We hypothesized that our cross-sectional observational study would allow us to compare the plasma microenvironment of 83 ESRD patients and display metabolic and inflammatory biomarker concentration changes between groups with and without a history of stroke, ACS, CHF, and CAD. Such biomarker concentration disturbances were observed in ESRD patients with known history of vascular comorbid conditions when compared with ESRD patients without such history. Plasma IL-1α elevation was observed in ESRD patients with history of stroke or CAD. This finding is consistent with the biomarker's known involvement in systemic pathways involving a proinflammatory state. Plasma leptin variations were found in both the stroke and CHF cohorts. A decreased plasma leptin concentration was seen in the þCHF cohort, compared with the -CHF cohort which is in line with the converse association of serum leptin concentration and cardiovascular disease-related mortality in stable maintenance hemodialysis patients. 19 In the þStroke cohort, however, an elevated plasma leptin concentration was observed which, we propose, may be primarily impacted by increased adiposity in these patients. ESRD patients with history of stroke were found to have significantly elevated 
Discussion
High levels of proinflammatory cytokines IL-1, IL-6, and TNF-α have been shown to be associated with decreased survival and worse outcomes in ESRD patients. 20 Such markers of inflammatory activity, including IL-6, have demonstrated correlation with vascular microanatomic changes in CKD patients, which provides insight into the pathophysiologic systemic etiology of the vast array of comorbid vascular conditions that arise in these complex patients. 21 These observations are corroborated by our observation of elevated IL-6 in ESRD patients with history of ACS. Future studies may be directed at elucidating details regarding the potential impact of IL-6 on the development of coronary microvascular pathology contributing to the anatomic disregulation seen clinically in ACS. Subsequent efforts may aggregate a substantially larger population and utilize a prospective design to evaluate ESRD patients throughout the progression of their respective disease processes. Such studies may provide much-needed diagnostic and prognostic data to be applied in predictive models in an effort to optimize the care of these patients. Clinically, plasma sampling of ESRD patients on hemodialysis may provide a future modality to risk stratify patients and provide justification for earlier intervention in risk populations.
Limitations
We note presence of limitations in our cross-sectional pilot study methods and design. Although many of our biomarkers are known to have rapid concentration changes in plasma, our primary aim was to illustrate a framework and initial observations in relation to the biomarker array's role in examining a snapshot of the complex ESRD patient's plasma microenvironment. We also acknowledge that our procedure of labeling patients in a binary fashion into groups with and without a given comorbidity is in many ways an over-simplification of the diversity seen in these conditions. In addition, larger sampling of this diverse population would further illuminate the presence or absence of metabolic and inflammatory derangements and therefore strengthen the correlations made. 
